The Report Guru

According to the new market research report  " Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software), Technology (ELISA, Rapid Test), Platform (Radioimmunoassay), Specimen, Application (Infectious Diseases, Oncology, Cardiology), End User (Hospitals) - Global Forecast to 2023" , The immunoassay market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%. The increasing incidence of chronic and infectious diseases, technological advancements in immunoassay instruments and introduction of novel automated systems, and growth in the biotechnology and biopharmaceutical industries are some the major factors driving the growth of this market. By product and service, the reagents and kits segment commanded the largest share of the market in 2017 On the basis product and service, this market is classified into reagents and kits, analyzers, and software and services. In 2017, the reagents and kits seg...

The pacemakers market is projected to reach USD 4.9 billion by 2023 from USD 4.4 billion in 2018, at a CAGR of 2.0% during the forecast period. The major driving factors in the pacemakers market are increasing prevalence of cardiovascular diseases and technological advancements in devices. The major pacemakers vendors include Medtronic (Ireland), Abbott (US), and Boston Scientific (US) BIOTRONIK (Germany), LivaNova (UK), OSCOR (US), Pacetronix (India), MEDICO (Italy), Osypka Medical (Germany), and Lepu Medical (China). These players have adopted various growth strategies such as expansions, acquisitions, and new product launches to expand their presence in the global pacemakers market. Product launches has been the most dominating strategy adopted by major players from 2015 to 2018. This has helped them to expand their consumer base and address the unmet needs of end users. To know the Insights  download the pdf brochure:   https://www.marketsandmarkets.com/pdfdownload...

Market growth factors The growing target patient population, ongoing technological advancements, favorable medical reimbursements, rising demand for minimally invasive thrombectomy procedures, and increasing healthcare expenditure across emerging markets are some key factors propelling the growth of this thrombectomy devices market. What experts says about the growth of this market? The global Thrombectomy devices market over the forecast period of 2017 to 2022. The market is expected to reach USD 1.45 Billion by 2022 growing at a CAGR of 6.7%. Thrombectomy Devices Market by Type (Hydrodynamic, Ultrasound, Aspiration, Mechanical Thrombectomy), Application (Cardiovascular, Peripheral, Neurovascular), End User (Hospitals, Surgical Centers, Ambulatory, Academia, CROs) - Global Forecasts to 2022 Download Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222966801    On the basis of type, the global thrombectomy devices market is segmented into...

Market growth factors Major growth drivers of the cancer biomarkers market are rising prevalence of cancer and rising demand for personalized medicine in cancer therapies. However, the high cost of various cancer diagnostic tests, need for high capital investments, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection are restricting the growth of this market. What experts says about the growth of this market? The global cancer biomarkers market is projected to reach USD 20.48 Billion by 2022 from USD 11.53 Billion in 2017, at a CAGR of 12.2%. Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022 Download Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202   The cancer biomarkers market on t...